Home Add to Favorite Contact Submit  
           25 September, 2020


    
Category:  Press » Technology

 

New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents

Popularity:
         Views: 1384
2009-11-30 06:14:23     
Cell Therapeutics, Inc.

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines. The results were presented in a paper titled "Novel Bis-platinum Complexes Endowed with an Improved Pharmacological Profile," by Laura Gatti et al. that was published in the online edition of the journal Molecular Pharmaceutics. Platinum-based compounds, such as cisplatin and oxaliplatin, are the cornerstone in the treatment of testicular, ovarian, colorectal, lung and other cancers but their effectiveness is limited by the relatively low therapeutic ratio, the ratio of the maximally tolerated dose of the drug to the effective dose, and the frequent occurrence of drug resistance leading to cancer recurrence. The novel bis-platinum compounds represent a completely new class of platinum-based drugs called bisplatinates.

The bis-platinum based compounds, unlike the currently approved platinum-based compounds, contain two platinum atoms and work by binding to and damaging both strands of DNA making it much more difficult for cancer cells to repair the damage. The research demonstrated through cancer cell assays and animal tumor models that the bis-platinum complexes exhibited greater cytotoxic potency and anti-tumor effect compared to cisplatin and oxaliplatin. There was more than a 200-fold increase in percent accumulation in tumor cells of the bisplatinum compounds compared to cisplatin and oxaliplatin. The bisplatinates were substantially more active against human tumors grown in an immunodeficient preclinical model than the standard palatinate compounds, oxaliplatin, carboplatin and cisplatin. Furthermore, the bis-platinum compounds demonstrated the ability to overcome tumor resistance to cisplatin mediated by DNA mismatch repair defects. The complexes showed marked anti-tumor efficacy in platinum refractory tumors, with significant activity in terms of tumor growth inhibition and tumor growth delay.

"Platinum-based compounds are cornerstone agents in the treatment of very common cancers such as cancers of the lung, colon, and ovary and are also widely used in other gynecological tumors, testicular cancers, and cancers of the esophagus, head and neck. They are increasingly being used for salvage therapy in lymphoma. However, resistance to palatinate compounds is common. The current results are encouraging as they demonstrate that the bisplatinates are not only more effective in human tumor models than the current agents, but also capable of overcoming some forms of palatinate resistance," said Jack Singer, M.D., Chief Medical Officer of CTI.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit our website.

Sign up for email alerts and get RSS feeds at our Web site.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with bis-platinum based compounds in particular, including, without limitation, the potential failure of bis-platinums to prove effective in inhibiting or delaying tumor growth or to overcome cisplatin resistance or to be safe or effective in animals or humans, that CTI does not enter clinical trials for the bis-platinates in 2010, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


Media Contact: Investors Contact:
Dan Eramian Ed Bell
T: 206.272.4343 T: 206.272.4345
C: 206.854.1200 Lindsey Jesch Logan
F: 206.272.4434 T: 206.272.4347

Specialized in: Biopharmaceutical - Cti - Therapeutics - Cell Therapeutics - Biotech - Cancer Therapy - Opaxio - Pixantrone - Brostallicin
URL: http://www.celltherapeutics.com
Print press release      Bookmark this page
Related Press releases 
Microchip Expands Adaptec SmartRAID Product Portfolio with New Entry-level Adapter (Popularity: ): New Delhi, June 30, 2020 — To support cloud, enterprise and workstation customers that require the robustness and performance of hardware RAID at an entry-level cost point, Microchip Technology Inc. (Nasdaq: MCHP) announces the Adaptec® SmartRAID 3100E RAID adapters which are designed to provide reliable hardware RAID protection for customer data in cost-sensitive end applications. The SmartRAID 3100E provides over 60 percent performance acceleration over Microchip’s prior-generation Adaptec Series 8E ...
Microchip Announces the 53100A Phase Noise Analyzer for Precision Oscillator Characterization (Popularity: ): New Delhi, May 5th, 2020 – To help research and manufacturing engineers make precise and accurate measurement of frequency signals, including those generated by atomic clocks and other high-performance frequency reference modules and subsystems, Microchip Technology Inc. (Nasdaq: MCHP) today announced the availability of the new 53100A Phase Noise Analyzer, a next-generation phase noise test instrument. The 53100A Phase Noise Analyzer is designed for engineers and scientists who rely on ...
Munich service robot can provide support during the COVID 19 pandemic (Popularity: ): Munich, Bavaria ( press.abc-directory.com ) April 8, 2020 - The technology company Robotise wants to help quickly alleviate current staff shortages in hospitals, doctors' practices and nursing homes.The company is modifying its JEEVES service robot for this purpose. The 1.10-meter-high robot has been used primarily for minibar and room service in hotels until now. But the robotic butler will now be used as an autonomous assistant for the health sector. ...
SWAT Environmental Announces Acquisition of Radon Specialists, Inc. (Popularity: ): New Berlin, WI (September 12, 2019) Soil, Water, and Air Technologies / SWAT Environmental, is pleased to announce the acquisition of Radon Specialists, Inc. of Wisconsin. The acquisition will make SWAT Environmental the leading radon mitigation and testing company in the midwest and further grow their national footprint. SWAT has been in business since 1988 and is the nation’s largest and most experienced radon mitigation company."We’re thrilled for the opportunity ...
BMX160 Absolute Orientation Sensor from Bosch Featured in THE EDGE by Future Electronics (Popularity: ): Montreal, Quebec ( press.abc-directory.com ) March 27, 2019 - Future Electronics, a global leading distributor of electronic components, is featuring the advanced BMX160 Absolute Orientation Sensor from Bosch in the latest edition of THE EDGE.The BMX160 is a very small, low power, low noise absolute orientation sensor designed for use in wearable devices like smart watches or augmented reality glasses. It comprises a 3-axis accelerometer, gyroscope and geomagnetic sensor in ...

Press release home snapshot 


Related Business 
Thorrko (Popularity: ): Specializing in providing platinum services to the trade, from platinum jewelry design to platinum casting. Based in Toronto.
Precision Therapeutics, Inc. (Popularity: ): Focusing on the interaction of cultivated tumor cells with chemotherapy and immunology-based drugs.
Platinum Construction & Design Pty Ltd. (Popularity: ): Platinum Construction & Design was started in 2010 and is and owner operated company. Platinum Construction & Design strives to ensure full customer satisfaction, with quality services at reasonable prices. Whether you want to add a deck to your backyard or have a demolition job, Platinum Construction & Design is the best option available in the market. Being a small to medium sized business Platinum Construction & Design has the ...
Platinum Heritage (Popularity: ): Platinum Heritage offers adventure desert safari tours in the pristine wildlife reserves in Dubai. Experience first class service & cuisines with Platinum Heritage. With expertise in not only luxury but culture, wildlife and history, Platinum Heritage reveals our destination with an authenticity beyond the reach of any other adventure tour company.
Platinum Mart (Popularity: ): Specializes in certified 85% pure platinum jewelry. Includes general platinum information and market data.
The Brain Tumor Foundation (Popularity: ): Supports patients and their families when their lives are affected by a brain tumor. Located in New York City.
American University of Beirut Medical Center (Popularity: ): Maintain a tumor registry and administer and keep records of regular interdisciplinary tumor conferences . Offers guiddes and protocols, photographs and history of the center.
Safety Direct America (Popularity: ): We Safetydirectamerica supply anti-slip floor and anti-slip bath treatment services, adhesive anti-slip/non-skid tapes, glow in the dark safety tapes, do-it-yourself clear abrasive anti-slip floor and bath coatings, colored anti-slip floor paint, and slip resistance (coefficient of friction) testing services.
Bauleke.com: Where a Brain Tumor Survivor Lives... (Popularity: ): A long-term survivor of a brain tumor stresses the importance of research.
Cancer Cure Pharmacy (Popularity: ): CancerCurePharmacy is a Speciality Drugs Pharmacy focused on Oncology (Anti-Cancer) Drugs and offering the most comprehensive range of Generic Anti-Cancer Medicines for an online purchase and dispatch directly from India.